Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Isocarboxazid. Efficacy and tolerance.

J Davidson, C Turnbull

    Journal of Affective Disorders
    |May 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Isocarboxazid demonstrated superior efficacy compared to placebo in a double-blind trial. Patients experiencing weight gain, increased appetite, and sleepiness showed rapid improvement within one week.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Anaesthesia for antireflux and achalasia surgery.

    BJA education·2026
    Same author

    Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

    Physical review letters·2026
    Same author

    Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

    Physical review letters·2025
    Same author

    Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

    Physical review letters·2025
    Same author

    Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same journal

    Corrigendum to "Choroid plexus enlargement correlates with cognitive impairment and brain atrophy in patients with mood disorders" [J. Affect. Disord. 379 (2025) 370-378].

    Journal of affective disorders·2026
    Same journal

    Long-term trajectories of basal metabolic rate and risk of depressive symptoms: evidence from three large population-based cohorts.

    Journal of affective disorders·2026
    Same journal

    An implementation "Field Trial" of DBT for adolescents with bipolar disorder: Training procedures and therapist outcomes.

    Journal of affective disorders·2026
    Same journal

    Anxiety and depression associated oral health problems in pediatric populations: A systematic review and meta-analysis.

    Journal of affective disorders·2026
    Same journal

    Corrigendum to "Suicidal ideation in the postpartum period: A population-based study of prevalence and risk factors using data from two national maternity surveys in England" [J. Affect. Disord. 389 (2025) 119707].

    Journal of affective disorders·2026
    Same journal

    Suicide mortality in Brazil: Post-pandemic excess mortality and spatial inequalities.

    Journal of affective disorders·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Clinical Psychiatry

    Background:

    • Monoamine oxidase inhibitors (MAOIs) are a class of antidepressants.
    • Assessing the efficacy and tolerability of isocarboxazid is crucial for treatment selection.

    Purpose of the Study:

    • To evaluate the efficacy and tolerability of isocarboxazid compared to placebo.
    • To identify patient subgroups that respond best to isocarboxazid treatment.

    Main Methods:

    • A double-blind, placebo-controlled study design was employed.
    • Flexible dosing of isocarboxazid was administered, with a modal range of 30-60 mg/day.
    • Patient response and side effects were systematically monitored.

    Main Results:

    • Isocarboxazid showed significantly greater efficacy than placebo.

    Related Experiment Videos

  • Patients with specific symptoms (weight gain, increased appetite, increased sleep) exhibited a rapid onset of improvement.
  • The modal effective dose was 30-60 mg/day; higher doses were poorly tolerated.
  • Common side effects included dizziness and myoclonus, generally mild.

    • Conclusions:

    • Isocarboxazid is an effective antidepressant, particularly for patients with certain symptom profiles.
    • A flexible dose range of 30-60 mg/day appears optimal for efficacy and tolerability.
    • Further research may explore personalized treatment approaches based on symptom presentation.